close

Enter

Log in using OpenID

Macular Edema Treatment Market Prognosticated For A Ravishing Growth By 2026

embed
Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an oval-shaped pigmented area near the center of retina. This blister causes the macula to swell and
Macular Edema Treatment Market Prognosticated
For A Ravishing Growth By 2026
Macular Edema Treatment Market, by Disease Type (Diabetic Macular Edema
and Cystoid Macular Edema), by Drug Class (Anti-Vascular Endothelial Growth
Factor (VEGF) Injections (Avastin, Eylea ,and Lucentis) and Anti-inflammatory
Medication (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroid
Implants (Ozurdex, Retisert, and Iluvien)), by End User (Hospitals, Ophthalmic
Clinics, and Research Institutes), and by Region (North America, Europe, Asia
Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and
Opportunity Analysis, 2018 – 2026
Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that
forms blister in the layer of macula. The macula is an oval-shaped pigmented area near the center of
retina. This blister causes the macula to swell and thicken that causes distortion of vision. Although
macular edema has numerous causes, the most common cause is diabetes. Other causes include, agerelated macular degeneration, replacement of lenses in treatment of cataract, chronic uveitis and
intermediate uveitis, blockage of vein in the retina, and congenital diseases including retinitis
pigmentosa and retinoschisis. Symptoms of macular edema include blurry or wavy vision near or in the
center of field of vision. The disease is diagnosed by performing tests such as visual acuity test,
dilated eye exam, fluorescein angiogram,optical coherence tomography, and Amsler grid. Click
To Read More On Macular Edema Treatment Market.
Macular Edema Treatment Market: Drivers
Increasing number of pipeline studies is expected to drive the macular edema treatment market growth.
For instance, in April 2018, University of California, Davis, in collaboration with IRIDEX Corporation,
initiated phase 3 clinical trial for Micropulse Laser Treatment to evaluate micropulse for suppression of
diabetic macular edema (pulse). The primary aim of the study is to determine whether the micropulse
laser treatment in eyes with good visual acuity will improve or stabilize vision loss due to the
complications of diabetic macular edema. The study is expected to be completed by December 2020.
Furthermore, increasing approval for new diabetic macular edema (DME) therapies is expected to
propel growth for the macular edema treatment market. For instance, in March 2018, U.S. Food and
Drug Administration (FDA) approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS)
for diabetic macular edema and diabetic retinopathy. Lucentis 0.3 mg PFS is the first syringe prefilled
with an anti-vascular endothelial growth factor (VEGF) agent. Moreover, in 2016 U.S.FDA approved
Lucentis 0.5 mg PFS, which is intended for use in the treatment of neovascular (wet) age-related
macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic
choroidal neovascularisation (mCNV).
Macular Edema Treatment Market: Regional Analysis
On the basis of region, the global macular edema treatment market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to account for the largest market share in the macular edema treatment
market, owing to increasing prevalence of diabetic macular edema in this region. For instance,
according to American Journal of Managed Care (AJMC), in 2016, the prevalence rate of diabetic
macular edema was 45.3% in North America.
Moreover, in 2013, as per National Center for Biotechnology Information (NCBI), around 98 million
individuals reported for diabetic retinopathy (DR) and 21 million individual reported for diabetic
macular edema (DME) worldwide.
Furthermore, increasing product approvals for the treatment of macular edema is expected to boost
growth of the macular edema treatment market in Europe. For instance, in 2015, the European
Commission approved Eylea (aflibercept) for the treatment of patients with macular edema secondary
to retinal vein occlusion. Bayer HealthCare and Regeneron collaborated to develop Eylea. Bayer
HealthCare has exclusive marketing rights to the product outside the U.S.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2494
Competitive Analysis
Key players operating in the macular edema treatment market include, Novartis International AG, F.
Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Pfizer Inc. Bayer AG, Aerpio Therapeutics,
Inc., Biomar Microbial Technologies, Antisense Therapeutics Limited, Coherus BioSciences, and
Bausch & Lomb Incorporated.
Macular Edema Treatment Market Taxonomy
By Disease Type
•Diabetic Macular Edema
•Cystoid Macular Edema
By Drug Class
•Anti-Vascular endothelial growth factor (VEGF) injections
•Avastin
•Eylea
•Lucentis
•Anti-inflammatory Medication
•Nonsteroidal anti-inflammatory drugs (NSAIDs)
•Corticosteroid
•Ozurdex
•Retisert
•Iluvien
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called
PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing
trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps
biotechnology and pharmaceutical companies to analyze the market trend, competition, and market
potential. For more information or to access this database, kindly click on the below link or contact at
[email protected]
https://www.coherentmarketinsights.com/phase-xs/
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran184   documents Email
Document
Category
Health and Medicine
Views
8
File Size
401 KB
Tags
treatment
1/--pages
Report inappropriate content